116 related articles for article (PubMed ID: 31583526)
1. Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.
Akahane T; Hirasawa A; Imoto I; Okubo A; Itoh M; Nanki Y; Yoshihama T; Tominaga E; Aoki D
Hum Cell; 2020 Jan; 33(1):272-282. PubMed ID: 31583526
[TBL] [Abstract][Full Text] [Related]
2. Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing.
Oumi N; Itamochi H; Komatsu H; Oishi T; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Kudoh A; Harada T
Hum Cell; 2016 Jan; 29(1):46-51. PubMed ID: 26070481
[TBL] [Abstract][Full Text] [Related]
3. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract][Full Text] [Related]
4. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
[TBL] [Abstract][Full Text] [Related]
5. Molecular Characterization of Peritoneal Mesotheliomas.
Offin M; Yang SR; Egger J; Jayakumaran G; Spencer RS; Lopardo J; Nash GM; Cercek A; Travis WD; Kris MG; Ladanyi M; Sauter JL; Zauderer MG
J Thorac Oncol; 2022 Mar; 17(3):455-460. PubMed ID: 34648949
[TBL] [Abstract][Full Text] [Related]
6. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC
Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124
[TBL] [Abstract][Full Text] [Related]
7. Multipotent cancer stem cells derived from human malignant peritoneal mesothelioma promote tumorigenesis.
Varghese S; Whipple R; Martin SS; Alexander HR
PLoS One; 2012; 7(12):e52825. PubMed ID: 23285196
[TBL] [Abstract][Full Text] [Related]
8. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
9. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.
Carlson B; Harmath C; Turaga K; Kindler HL; Armato SG; Straus C
Abdom Radiol (NY); 2022 May; 47(5):1725-1740. PubMed ID: 35257201
[TBL] [Abstract][Full Text] [Related]
10. Clinical, histologic, and genetic features of mesothelioma in a 7-year-old child.
Sugalski A; Davis M; Prasannan L; Saldivar V; Hung JY; Tomlinson GE
Pediatr Blood Cancer; 2013 Jan; 60(1):146-8. PubMed ID: 22961710
[TBL] [Abstract][Full Text] [Related]
11. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.
Napolitano A; Pellegrini L; Dey A; Larson D; Tanji M; Flores EG; Kendrick B; Lapid D; Powers A; Kanodia S; Pastorino S; Pass HI; Dixit V; Yang H; Carbone M
Oncogene; 2016 Apr; 35(15):1996-2002. PubMed ID: 26119930
[TBL] [Abstract][Full Text] [Related]
12. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.
Lee YK; Jun HJ; Nahm JH; Lim TS; Park JS; Ahn JB; Rha SY; Chung HC; Oh HE; Song JS; Yang WI; Kim HS
Jpn J Clin Oncol; 2013 Oct; 43(10):996-1003. PubMed ID: 23964112
[TBL] [Abstract][Full Text] [Related]
14. Complete pathological response to neoadjuvant pemetrexed/cisplatin in combination with regional hyperthermia in a patient with sarcomatoid peritoneal mesothelioma.
Kruger S; Angele MK; Reu S; Sotlar K; Graser A; Haas M; Albertsmeier M; Stemmler HJ; Heinemann V; Lindner LH; Boeck S
Anticancer Drugs; 2014 Aug; 25(7):854-6. PubMed ID: 24637577
[TBL] [Abstract][Full Text] [Related]
15. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
16. Malignant peritoneal mesothelioma.
Loggie BW
Curr Treat Options Oncol; 2001 Oct; 2(5):395-9. PubMed ID: 12057102
[TBL] [Abstract][Full Text] [Related]
17. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
Hassan R; Alexander R; Antman K; Boffetta P; Churg A; Coit D; Hausner P; Kennedy R; Kindler H; Metintas M; Mutti L; Onda M; Pass H; Premkumar A; Roggli V; Sterman D; Sugarbaker P; Taub R; Verschraegen C
Ann Oncol; 2006 Nov; 17(11):1615-9. PubMed ID: 16600983
[TBL] [Abstract][Full Text] [Related]
18. Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort.
Vlastos F; Hillas G; Vidal P; Lacomme S; Galateau-Sallé F; Vollmer E; Guzman-Costabel J; Vignaud JM; Martinet N
J Thorac Oncol; 2009 Oct; 4(10):1259-63. PubMed ID: 19546821
[TBL] [Abstract][Full Text] [Related]
19. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
20. Diffuse malignant peritoneal mesothelioma--an update on treatment.
Mirarabshahii P; Pillai K; Chua TC; Pourgholami MH; Morris DL
Cancer Treat Rev; 2012 Oct; 38(6):605-12. PubMed ID: 22104079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
